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Abstract
Background: HIV testing on sputum using the QraQuick HIV1/2® assay has high sensitivity and
specificity, and holds promise for application in tuberculosis surveys. Its performance under
conditions that may occur during surveys in resource-poor countries is however, unknown. We
assessed, in a blinded comparison with HIV serum testing, the sensitivity and specificity of the
OraQuick® assay for detecting HIV antibody in sputum specimens kept at ambient temperature for
up to 7 days, with and without decontaminant.
Methods:  Paired sputum and blood specimens from consecutively diagnosed smear-positive
tuberculosis patients were tested with OraQuick® and 2 HIV-1/2 ELISA's. Sputum was tested within
24 hours of collection, split into 2 aliquots with and without addition of cetylpyridium chloride, and
tested again after 4 and 7 days.
Results: Complete data was available for 377/435 (87%) enrolled patients; 132 (35%) tested HIV
positive on serum. The sensitivity of the sputum test was 94.7% (95% CI 89.4–97.8) on day 1, 93.2%
on day 4 and 92.9% on day 7. The specificity was 92.9% (95% CI 88.9–95.8) on day 1, and declined
to 76.7% on day 4 (p < 0.001) and to 62.7% on day 7 (p < 0.001). Adding cetylpyridium chloride
further decreased the specificity to 67.8% on day 4 (p = 0.04) and to 49.6% on day 7 (p = 0.004).
Conclusion: Transportation of sputum specimens at ambient temperatures for 4 days or more,
and addition of decontaminant, strongly affect the specificity of the OraQuick® assay. Unless applied
within one day, this assay is not suitable for estimation of HIV-prevalence among tuberculosis
patients in survey settings.
Background
The HIV epidemic has strongly increased tuberculosis
incidences, in particular in sub-Saharan Africa [1]. For
planning and evaluation of control efforts it is important
to monitor the proportion of tuberculosis patients that is
HIV-infected [2,3]. In settings with generalized HIV epi-
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demics, as in most of Sub-Saharan Africa, the preferred
method is surveillance based on routine HIV testing of
every tuberculosis patient [3]. As long as access to HIV
testing and antiretroviral treatment is limited [4], many
countries need to rely on repeated surveys in which ran-
domly selected tuberculosis patients are tested for HIV
infection [3,5,6]. In such surveys, serum HIV testing poses
problems of feasibility and requires informed consent,
with the risk of non-participation and associated selection
bias [3]. An attractive alternative is to detect HIV antibod-
ies in sputum specimens [7,8]. This can be added onto
surveys of tuberculosis patients in which sputum is col-
lected, in particular for drug susceptibility testing. HIV
testing can be centralized in one or few laboratories, and
since sputum is already collected for other purposes,
informed consent would not be needed, provided that
anonymity and unlinking are safeguarded [8,9]. In order
to be useful for this purpose, HIV testing on sputum
should have sufficient sensitivity and specificity under
conditions that apply in tuberculosis drug resistance sur-
veys in high-prevalence countries. These include transit
times between collection and processing of sputum speci-
mens of up to 4 and sometimes to 7 days, specimen trans-
port at high ambient temperatures and, if prolonged
transit is expected, addition of cetylpyridiniumchloride
(CPC) or cetylpyridiniumbromide (CPB) to minimize
bacterial contamination [10,11].
In an evaluation on clinical specimens, the OraQuick
HIV-1/2® Assay, a lateral flow test that has been FDA
approved for HIV testing on oral fluids, detected HIV anti-
bodies in sputum with 98.4% sensitivity and 98.3% spe-
cificity on the day of collection [7]. Although specificity
remained unaffected, sensitivity declined to 94.0% when
specimens were tested more than 72 hours after collection
but stored refrigerated. Based on these results the
OraQuick test was used in a drug resistance survey among
tuberculosis patients in Botswana [8].
We assessed the impact of prolonged storage at ambient
temperatures and of addition of CPC on the diagnostic
accuracy of the OraQuick test for detection of HIV anti-
bodies in sputum samples.
Methods
Study design
In a prospective study among smear-positive tuberculosis
patients in Dar-es-Salaam, Tanzania, the sensitivity and
specificity of the OraQuick HIV antibody test on sputum
specimens was assessed on the day of collection and 4 and
7 days later, with and without CPC, in blinded compari-
son using the result of two HIV enzyme immunoassays on
serum as the reference standard.
Participants
The study was conducted in six tuberculosis facilities in
Dar-es-Salaam that diagnose and treat tuberculosis
mainly on an outpatient basis. Eligible for inclusion were
all patients aged ≥ 15 years who were consecutively diag-
nosed with sputum smear-positive tuberculosis during
the period 1 November – 31 December 2004. There were
no exclusion criteria. The study period was chosen to
include approximately 400 patients. This sample size was
based on the assumptions of 33% HIV prevalence among
included patients and an observed sensitivity 94%, and
on the requirement to estimate this sensitivity with a
lower boundary of the 95% confidence interval (CI) of
90%. With this sample size, the lower boundary of the
95% CI for an observed specificity of 98% would be 94%.
Specimen collection
Of each included patient, one sputum specimen and one
blood specimen were collected. Sputum specimens were
collected in sterile universal glass containers following
standard procedures and transported to the laboratory on
the same day [10]. Approximately 5 ml of venapuncture
blood was transported to the laboratory within four hours
of collection.
Specimen processing and testing
Detection of HIV antibodies in sputum was done at the
Central Tuberculosis Reference Laboratory (CTRL), and
HIV serum testing in the Department of Microbiology and
Immunology of the Muhimbili University College of
Health Sciences (MUCHS), both in Dar-es-Salaam. Spu-
tum samples were tested for HIV antibodies using the
OraQuick HIV-1/2® Assay on the day of collection (day 0)
and then apportioned into two aliquots. One aliquot was
placed into a sterile universal glass bottle containing an
equal volume of CPC 1.0% while the other was kept in a
non-CPC containing bottle [10]. Both aliquots were
stored at ambient temperature until 96 to 120 hours after
collection (day 4) when the specimens were tested using
the OraQuick assay. These samples were then stored at
ambient temperature until 168 to 192 hours after collec-
tion (day 7) and tested again. OraQuick testing was per-
formed by two designated laboratory technicians
following the manufacturer's recommendations (OraSure
Technologies Products, Bethlehem, PA 18015, Ph.
610.882.1820). Briefly, the porous flat pad of the
OraQuick device was stirred in the sputum specimen for
at least 60 seconds, placed in the developer vial and read
after 20 to 60 minutes. If the control line was not visible,
a test was considered uninterpretable. If no lines appeared
and the sputum was viscous, an equal volume of normal
saline was added to dilute the sputum and the test was
repeated using a fresh device [7].BMC Clinical Pathology 2007, 7:8 http://www.biomedcentral.com/1472-6890/7/8
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Detection of IgG HIV antibody in serum was done using
Vironostika HIV Uni-Form II Ag/Ab (BioMerieux, Boxtel,
The Netherlands) and reactive samples were retested by
Vironostika HIV Uni-Form II Plus O (BioMerieux, Boxtel,
The Netherlands). Samples reactive on both tests were
considered to contain IgG anti HIV antibodies. The tech-
nicians performing the sputum assay were blinded to the
results of the serum assays, and vice versa.
Two weeks after the start of the study, data monitoring by
one of the authors (FGC) revealed a remarkable discrep-
ancy in sputum testing results between day 0 and day 4
that suggested declining specificity over time. We hypoth-
esized that this decline in specificity was an artifact of our
study design, i.e. was due to cross-contamination between
sputum specimens resulting from difficulties in splitting
the viscous material. To be able to assess possible cross-
contamination during the splitting procedure on day 0, all
sputum specimens received from 29 November through
12 December were left un-split and tested without CPC
only. The technicians performing the sputum assay were
not informed about the reason for this temporary change
in procedure.
Ethical issues
The study was conducted in compliance with the Helsinki
Declaration [12]. Ethical clearance was granted by the
Tanzania National Institute for Medical Research. Written
informed consent was obtained from each patient prior to
enrolment after explaining the objectives of the study,
risks and benefits of participation. Study patients could
choose to either or not obtain the result of their serum
HIV test. Pre-test and, in case the participant opted to
obtain the result, post-test counseling for HIV testing was
done according to national guidelines. If informed of
their test result, HIV positive patients were referred to the
nearest HIV clinic for further management.
Data management and analysis
Data was entered in duplicate in MS-Excel (Microsoft
Corp., Seattle WA) and discrepancies were checked against
the forms and laboratory records. Analysis was done using
Stata v8 (Stata Corp., College Station TX). Sensitivity was
calculated as (number positive on sputum/number posi-
tive on serum)*100. Specificity was calculated as (number
negative on sputum/number negative on serum)*100.
Testing for significance of categorical variables was with
the Chi-squared test or the 2-sided Fisher's exact test, and
of continuous variables with the t-test or Wilcoxon's rank
sum test as appropriate. P-values < 0.05 were considered
significant.
Results
A total of 381 blood samples and 434 sputum samples
were obtained from 435 patients. Complete data were
available for 377 (87%, figure 1). Of these, 255 (68%)
were between 15 and 34 years and 253 (67%) were male.
There were no differences in age and sex between included
and not included patients, but the proportion included
varied significantly by clinic (Table 1). HIV results on spu-
tum specimens without CPC were available for all 377
patients on day 1 and day 4. Due to insufficient material
left for testing, 54 (14%) specimens were not tested on
day 7 (figure 1). Eighty-three specimens had not been split
on day 1 and were evaluated without CPC, and there were
additional losses of sputum specimens with CPC for day
7. Therefore, results were available on days 4 and 7 with
CPC for 284/377 (75%) and 225/323 patients (70%),
respectively. Because some sputum specimens that tested
negative on day 4 had been erroneously discarded. the
proportion of sputum specimens that were available for
testing on day 7 was lower if the day 4 test was negative
than if it was positive, both without CPC (63% versus
93%, p < 0.01) and with CPC (50% versus 95%, p < 0.01).
The proportion of indeterminate sputum results was less
than 1.5% on any testing occasion.
Of the 377 patients in the analysis, 132 (35%) had a pos-
itive HIV serum result. The sensitivity of the sputum HIV
test on day 1 was 94.7% (95% CI 89.4–97.8), and showed
no significant change over time, neither with nor without
adding CPC (figure 1). The specificity of the sputum HIV
test on day 1 was 92.9% (95% CI 88.9–95.8). It decreased
significantly over time, both when compared to day 1
(day 4 and 7, both with and without CPC: p < 0.01 for
each comparison) and for day 7 versus day 4 (without and
with CPC, p < 0.01 for both; Table 2). The specificity with
CPC was significantly lower than without CPC, both on
Table 1: Characteristics of 377 included and 58 excluded patients 
with smear-positive tuberculosis
Included 
N = 377
Not included 
N = 58
P
Age groups (years) 0.18
15–24 96 (25%) 15 (26%)
25–34 159 (42%) 20 (35%)
35–44 55 (14%) 16 (27%)
45–54 42 (11%) 3 (5%)
55–64 13 (4%) 1 (2%)
65+ 12 (3%) 3 (5%)
Age (mean, Sd) 32.5 (12%) 33.7 (12%) 0.40
Male 253 (67%) 39 (67%) 0.98
Female 124 (33%) 19 (33%)
Clinic of inclusion < 0.01
Tambukareli 32 (9%) 1 (2%)
Temeke 41 (11%) 9 (16%)
Amana 102 (27%) 11 (20%)
Mnazi Mmoja 45 (12%) 23 (40%)
Tandale 58 (15%) 12 (21%)
Mwananyamala 99 (26%) 1 (2%)BMC Clinical Pathology 2007, 7:8 http://www.biomedcentral.com/1472-6890/7/8
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day 4 (67.8 vs 76.7%, p = 0.04) and on day 7 (49.6 vs
62.7%, p < 0.01).
We tested the hypothesis that the observed decline in spe-
cificity was due to cross-contamination between sputum
specimens during the splitting procedure by comparing
sensitivity and specificity of the sputum test over time in
the 83 specimens that were not split on day 1, and were
tested without CPC on days 4 and 7. These specimens
showed no differences in sensitivity when compared with
split specimens, neither on day 4 (p = 0.89) nor on day 7
(p = 0.74; Table 3). On day 4 the specificity was lower on
split than on unsplit samples (73.7 vs 87.3%, p = 0.03).
On day 7 the specificity was also lower on split samples
(59.3 vs 72.9%), but the difference remained non-signifi-
cant (p = 0.09).
Of 377 included sputum specimens, 321 (85.1%) had
been processed and tested by one technician, 32 (8.5%)
by another. For 24 specimens the technician had not been
recorded. Mean sensitivity or mean specificity of the spu-
tum HIV test showed no significant differences between
the two technicians (data not shown).
Discussion
Our results show that HIV testing using the OraQuick
HIV-1/2® Assay on sputum specimens of smear-positive
tuberculosis patients had more than 90% sensitivity and
Numbers of patients enrolled and numbers of sputum specimens available for the analyses Figure 1
Numbers of patients enrolled and numbers of sputum specimens available for the analyses. Numbers of patients 
enrolled and numbers of sputum specimens available for the analyses by HIV ELISA results on serum (standard test), day of 
testing and addition of cetylpyridiniumchloride (CPC). Data for day 1, day 4 and day 7 refer to HIV testing on sputum speci-
mens. Percentages refer to proportion of specimens with available test result out of number of patients tested positive or neg-
ative with the HIV ELISA on serum. †: Percentage of 105 specimens with CPC added. ¶: Percentage of 189 specimens with 
CPC added.
Enrolled: 435
Included in analysis: 377 (87%)
Serum HIV positive 
132 (35%)
Day 1
Day 4
Day 7
No serum received: 54 
No sputum received: 1 
Incomplete data: 3
Indeterminate: 0
Results available: 132 (100%)
Serum HIV negative 
245 (65%)
Indeterminate: 5
Results available 240 (98%)
No CPC added: 27 No CPC added: 56
Without CPC With CPC 
Note done: 0
Indeterminate: 0
Results available: 
132 (100%)
Note done: 5
Indeterminate: 1
Results available: 
99 (94%)†
Not done: 5
Indeterminate: 0
Results available: 
127 (96%)
Not done: 6
Indeterminate: 0
Results available: 
99 (94%)†
Without CPC With CPC 
Note done: 0
Indeterminate: 4
Results available: 
241 (98%)
Not done: 5
Indeterminate: 4
Results available:  
180 (95%)¶
Not done: 49
Indeterminate: 3
Results available: 
193 (79%)
Not done: 63
Indeterminate: 1
Results available: 
125 (66%)¶BMC Clinical Pathology 2007, 7:8 http://www.biomedcentral.com/1472-6890/7/8
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specificity for detecting HIV-antibodies if done on the day
of sputum collection. Although slightly lower than
reported from a study using clinical specimens of tubercu-
losis patients in Botswana [7], these may be considered
high enough for this test to be applied in surveys of HIV-
infection among tuberculosis patients in settings with
high expected HIV-prevalence. For example, with the
prevalence of HIV infection (35%) and specificity on day
1 (93%) observed in the current study, the positive predic-
tive value of the sputum HIV test can be calculated as
88%, i.e. no more than 12% of positive sputum tests
would be false-positive. This would still provide a reason-
ably valid estimate of the HIV prevalence in this patient
population.
When the sputum test was done 4 days after collection,
the specificity decreased significantly to 77% for speci-
mens without and to 68% for specimens with CPC. In a
setting of 35% HIV prevalence, this would correspond to
proportions false-positive of 31 and 39%, respectively.
With 10% HIV prevalence, the minimum prevalence at
which WHO allows the use of sputum HIV testing [3], the
corresponding proportions false-positive would be as
high as 69% and 75%, whereas they would still be 19%
and 25% at a very high prevalence of 50%. We think that
such false-positive rates are too high for surveillance pur-
poses. Delay to 7 days decreased the specificity even fur-
ther to only 63% and 50%, respectively, with further
increases in corresponding proportions false-positive.
Our results could also mean that the sensitivity of the spu-
tum test was higher than that of the reference standard. It
is however, unlikely that the high sensitivity of the com-
bined serum enzyme immunoassays used in this study
(99.7% in the same setting, 95% CI 98.2 – 100%) is sur-
passed by that of the sputum test [13].
From the presented data it seemed that adding CPC fur-
ther decreased the specificity. However, this reflects at
least in part the higher specificity on specimens that were
not split during a two-week period when all unsplit spec-
imens had been tested without CPC. The difference in spe-
cificity between split and unsplit specimens may also
point to a possible explanation for the decrease in specif-
icity over time. During the splitting procedure cross-con-
tamination of specimens may have occurred whereby HIV
antibody results became false-positive upon subsequent
testing. However, the differences in specificity between
Table 3: Sensitivity and specificity of HIV testing on sputum 
without CPC, comparing split and unsplit specimens
HIV serum ELISA 
(Standard)
HIV on 
sputum
Positive Negative Sensitivity 
(95% CI)
Specificity 
(95% CI)
Split specimens
Day 4 93.3% 
(86.7–97.3%)
73.7% 
(66.7–79.8%)
Positive 98 51
Negative 7 135
Total 105 186
Day 7 93.3% 
(86.6–97.3%)
59.3% 
(50.8–67.4%)
Positive 97 59
Negative 7 86
Total 104 145
Unsplit specimens
Day 4 92.6% 
(75.7–99.1%)
87.3% 
(75.5–94.7%)
Positive 25 7
Negative 2 48
Total 27 55
Day 7 91.3% 
(72.0–98.9%)
72.9% 
(58.2–84.7%)
Positive 21 13
Negative 2 35
Total 23 48
Table 2: Sensitivity and specificity of HIV testing on sputum at 
various days, with and without CPC
HIV serum ELISA 
(Standard)
HIV on 
sputum
Positive Negative Sensitivity 
(95% CI)
Specificity 
(95% CI)
Day 1 94.7% 
(89.4–97.8%)
92.9% 
(88.9–95.8%)
Positive 125 7
Negative 7 233
Total 132 240
Without CPC
Day 4 93.2% 
(87.5–96.8%)
76.7% 
(70.9–81.9%)
Positive 123 56
Negative 9 185
Total 132 241
Day 7 92.9% 
(87.0–96.7%)
62.7% 
(55.5–69.5%)
Positive 118 72
Negative 9 121
Total 127 193
With CPC
Day 4 93.9% 
(87.3–97.7%)
67.8% 
(60.4–74.5%)
Positive 93 58
Negative 6 122
Total 99 180
Day 7 94.9% 
(87.5–97.9%)
49.6% 
(40.5–58.7%)
Positive 94 63
Negative 5 62
Total 99 125BMC Clinical Pathology 2007, 7:8 http://www.biomedcentral.com/1472-6890/7/8
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split and unsplit specimens were only marginally signifi-
cant. In addition, there was a further and significant
decrease in specificity between day 4 and day 7, which is
unlikely to be due to cross-contamination during the
splitting procedure.
Another source of bias in the specificity estimate could be
that the 15–20% specimens that were not tested on day 7
were more often negative on day 4 than were the speci-
mens that were tested on day 7. If all specimens that were
not tested on day 7 would have tested HIV negative, the
specificity on day 7 would be 70.2% (170 of 242) for spec-
imens without and 66.5% (125 of 188) for specimens
with CPC. Thus, the difference between day 4 and day 7
may be partially explained by this bias.
However, these potential biases do not affect our conclu-
sions of a remarkable decrease in specificity over time. The
cause of this decrease is unclear. An earlier evaluation on
clinical sputum specimens in Botswana observed no such
decrease over a 3-day period, but specimens were kept
refrigerated [7]. It may thus be that when kept at ambient
temperatures, as expected in a countrywide anti-tubercu-
losis drug resistance survey, specimens change in such a
way that cross-reacting substances are generated. In addi-
tion, liquefaction of the sputum specimen over time could
contribute to false-positive readings, perhaps due to dif-
ferent absorption by the testing device. This poses a
research question for further study.
Conclusion
Unless testing within one day after sputum collection can
be guaranteed, HIV testing on sputum using the OraQuick
HIV-1/2® Assay is not suitable for use in tuberculosis drug
resistance surveys for the purpose of obtaining a valid esti-
mate of the HIV-prevalence among tuberculosis patients.
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